Jaguar Health (JAGX) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenue was $2.2 million, down 6% year-over-year and 37% sequentially from Q4 2024, primarily due to higher inventory levels at the end of 2024; Mytesi prescription volume rose 1.8% year-over-year but fell 13.5% sequentially, indicating rising patient demand.

• Net loss attributable to common shareholders was $10.5 million, up from $9.2 million in Q1 2024; loss from operations increased to $9.4 million from $8.2 million.

• Mytesi remains the primary revenue driver; Gelclair launched in Q4 2024 contributed to revenue and increased sales/marketing expenses.

• Significant clinical milestones achieved, including proof-of-concept results for crofelemer in ultra-rare diseases (MVID and SBSIF), showing reductions in TPN dependence.

• Management is focused on securing additional financing, expanding commercial footprint, and pursuing licensing and business development opportunities.

Financial highlights

• Net product revenue for Q1 2025 was $2.2 million, down 6% year-over-year and 37% sequentially; gross product sales were $3.2 million, with net product sales of $2.17 million after rebates and discounts.

• Operating expenses rose 10.1% to $11.6 million, driven by higher sales, marketing, and G&A costs.

• R&D expenses decreased to $3.7 million from $4.3 million due to completion of the Phase 3 OnTarget trial.

• Sales and marketing expenses rose to $2.5 million from $1.4 million, reflecting new product launches.

• Cash used in operating activities was $7.3 million; cash provided by financing activities was $5.0 million, mainly from convertible notes and ATM equity sales.

Outlook and guidance

• Ongoing and upcoming clinical trials in rare diseases and cancer supportive care expected to yield results throughout 2025 and into 2026.

• Additional proof-of-concept results for crofelemer in MVID and SBS-IF expected throughout 2025; FDA meeting scheduled in Q2 2025 to discuss Phase 3 OnTarget trial results in breast cancer subgroup.

• Management expects continued losses and increased expenditures as product development and commercialization efforts expand; additional financing is required to fund operations beyond the next year.

• Business development and licensing deals targeted to bring in non-dilutive funding.